An Observational, Prospective Cohort Study to Evaluate Safety and Efficacy of Remsima in Patients With Rheumatoid Arthritis

Trial Profile

An Observational, Prospective Cohort Study to Evaluate Safety and Efficacy of Remsima in Patients With Rheumatoid Arthritis

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 19 Jun 2017

At a glance

  • Drugs Infliximab (Primary) ; Anti-TNF monoclonal antibodies
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions
  • Sponsors Celltrion
  • Most Recent Events

    • 17 Jun 2017 Results from korean population presented at the 18th Annual Congress of the European League Against Rheumatism
    • 12 Jun 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Dec 2019.
    • 25 Sep 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top